Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells

Biochemical Pharmacology

Volumn 85, Issue 2, 2013, Pages 265-273

  Weiss, Johanna ^a   Theile, Dirk ^a   Spalwisz, Adriana ^a   Burhenne, Jürgen ^a   Riedel, Klaus Dieter ^a   Haefeli, Walter Emil ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Ambrisentan; Bosentan; Induction; Sildenafil; Tadalafil

Indexed keywords

AMBRISENTAN; BOSENTAN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PREGNANE X RECEPTOR; SILDENAFIL; TADALAFIL;

ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; EMBRYO; ENZYME INDUCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY;

ANTIHYPERTENSIVE AGENTS; BIOLOGICAL TRANSPORT; CARBOLINES; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; INTESTINAL ABSORPTION; INTESTINES; P-GLYCOPROTEIN; PHENYLPROPIONATES; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROMOTER REGIONS, GENETIC; PURINES; PYRIDAZINES; RECEPTOR, ENDOTHELIN A; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RECOMBINANT PROTEINS; RNA, MESSENGER; SULFONAMIDES; SULFONES;

EID: 84872009154     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.11.020     Document Type: Article

References (26)

1. N. Galiè, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, and J.A. Barbera Guidelines for the diagnosis and treatment of pulmonary hypertension Eur Respir J 34 2009 1219 1263
2. H.A. Ghofrani, O. Distler, F. Gerhardt, M. Gorenflo, E. Grünig, and W.E. Haefeli Treatment of pulmonary arterial hypertension (PAH): updated recommendations of the Cologne Consensus Conference 2011 Int J Cardiol 152S 2011 S20 S33
3. J.D. Croxtall, and S.J. Keam Ambrisentan Drugs 68 2008 2195 2204
4. J.C. Hartman, K. Brouwer, A. Mandagere, L. Melvin, and R. Gorczynski Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes Can J Physiol Pharmacol 88 2010 682 691
5. A. Treiber, R. Schneiter, S. Häusler, and B. Stieger Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil Drug Metab Dispos 35 2007 1400 1407
6. J. Dingemanse, and P.L. van Giersbergen Clinical pharmacology of bosentan, a dual endothelin receptor antagonist Clin Pharmacokinet 43 2004 1089 1115
7. S.J. Shukla, S. Sakamuru, R. Huang, T.A. Moeller, P. Shinn, and D. Vanleer Identification of clinically used drugs that activate pregnane X receptors Drug Metab Dispos 39 2011 151 159
8. J. Venitz, J. Zack, H. Gillies, M. Allard, J. Regnault, and C. Dufton Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension J Clin Pharmacol 52 2012 1784 1805
9. G. Burgess, H. Hoogkamer, L. Collings, and J. Dingemanse Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil Eur J Clin Pharmacol 64 2008 43 50
10. R.E. Wrishko, J. Dingemanse, A. Yu, C. Darstein, D.L. Phillips, and M.I. Mitchell Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects J Clin Pharmacol 48 2008 610 618
11. R. Spence, A. Mandagere, C. Dufton, and J. Venitz Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers J Clin Pharmacol 48 2008 1451 1459
12. R. Spence, A. Mandagere, B. Harrison, C. Dufton, and R. Boinpally No clinically relevant pharmacokientic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers J Pharm Sci 98 2009 4962 4974
13. J. Weiss, M. Herzog, and W.E. Haefeli Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro Eur J Pharmacol 660 2011 298 304
14. A. Gupta, G.M. Mugundu, P.B. Desai, K.E. Thummel, and J.D. Unadkat Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors Drug Metab Dispos 36 2008 1172 1180
15. S.K. König, M. Herzog, D. Theile, N. Zembruski, W.E. Haefeli, and J. Weiss Impact of drug transporters for the cellular resistance towards saquinavir and darunavir J Antimicrob Chemother 65 2012 2319 2328
16. S. Harmsen, A.S. Koster, J.H. Beijnen, J.H. Schellens, and I. Meijerman Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction Drug Metab Dispos 36 2008 1166 1171
17. T. Peters, H. Lindenmaier, W.E. Haefeli, and J. Weiss Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein Naunyn Schmiedebergs Arch Pharmacol 372 2006 291 299
18. J. Vandesompele, K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, and A. De Paepe Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol 3 2002 [RESEARCH0034]
19. J. Weiss, N. Weis, N. Ketabi-Kiyanvash, C.H. Storch, and W.E. Haefeli Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors Eur J Pharmacol 579 2008 104 109
20. X. Gu, S. Ke, D. Liu, T. Sheng, P.E. Thomas, and A.B. Rabson Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents J Biol Chem 281 2006 17882 17889
21. D. Bednarczyk Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3 Anal Biochem 405 2010 50 58
22. J. König, Y. Cui, A.T. Nies, and D. Keppler Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide J Biol Chem 275 2000 23161 23168
23. J. König, Y. Cui, A.T. Nies, and D. Keppler A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane Am J Physiol Gastrointest Liver Physiol 278 2000 G156 G164
24. V.P. Shah, K.K. Midha, S. Dighe, I.J. McGilveray, J.P. Skelly, and A. Yacobi Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report Eur J Drug Metab Pharmacokinet 16 1991 249 255
25. B.J. Ring, B.E. Patterson, M.I. Mitchell, M. Vandenbranden, J. Gillespie, and A.W. Bedding Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo Clin Pharmacol Ther 77 2005 63 75
26. A. Poirier, T. Lavé, R. Portmann, M.E. Brun, F. Senner, and M. Kansy Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model Drug Metab Dispos 36 2008 2434 2444